Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.44 |
| ▸ | CTSL | P07711 | 11/20 | 0.36 |
| ▸ | CTSK | P43235 | 11/20 | 0.34 |
| ▸ | CTSB | P07858 | 8/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8251702 | 0.90 | CTSS (0.46) | CTSSCTSLCTSKCTSB | |
| SCHEMBL8258105 | 0.88 | CTSS (0.41) | CTSSCTSLCTSKCTSB | |
| SCHEMBL6502940 | 0.84 | CTSL (0.35) | CTSSCTSLCTSKCTSBDRD2 | |
| SCHEMBL8258104 | 0.83 | CTSS (0.44) | CTSSCTSLCTSKCTSB | |
| SCHEMBL6213123 | 0.82 | CTSS (0.51) | CTSSCTSLCTSKCTSB | |
| SCHEMBL6658321 | 0.81 | CTSL (0.44) | CTSSCTSLCTSKCTSB | |
| SCHEMBL7685576 | 0.79 | CTSL (0.38) | CTSSCTSLCTSKCTSB | |
| SCHEMBL4828733 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL6210402 | 0.77 | CTSS (0.43) | CTSSCTSLCTSKCTSB | |
| SCHEMBL8256796 | 0.77 | CTSS (0.44) | CTSSCTSLCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465745-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465745-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7326719-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326719-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040180886-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040180886-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180886-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 10/4885CTSK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.